1. Home
  2. BIVI

BIVI

BioVie Inc.

Logo BioVie Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-23-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Founded: 2013 Country:
N/A
Employees: N/A City: CARSON CITY
Market Cap: 26.7M IPO Year: N/A
Target Price: $8.00 AVG Volume (30 days): 2.6M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.17 EPS Growth: N/A
52 Week Low/High: $0.45 - $8.69 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of BioVie Inc. (BIVI)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
DO CUONG V BIVI President & CEO Nov 30 '23 Buy $1.78 10,000 $17,800.00 68,759 SEC Form 4
GORLIN STEVE BIVI Director Nov 9 '23 Sell $1.69 75,680 $127,899.20 46,358 SEC Form 4